Hodgkin's Lymphoma News and Research RSS Feed - Hodgkin's Lymphoma News and Research

Hodgkin's lymphoma, previously known as Hodgkin's disease, is a type of lymphoma, which is a type of cancer originating from white blood cells called lymphocytes. It was named after Thomas Hodgkin, who first described abnormalities in the lymph system in 1832.
Sylvester researchers test new KTE-C19 therapy for patients with aggressive non-Hodgkin's lymphoma

Sylvester researchers test new KTE-C19 therapy for patients with aggressive non-Hodgkin's lymphoma

Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine are testing a novel cellular immunotherapy approach to treating patients with diffuse large B-cell lymphoma who have failed standard therapy. [More]
Gut bacteria linked to risk of bloodstream infections after chemotherapy

Gut bacteria linked to risk of bloodstream infections after chemotherapy

A new study led by researchers at the University of Minnesota and Nantes University Hospital in France shows that the bacteria in people's gut may predict their risk of life-threatening blood infections following high-dose chemotherapy. [More]
Early screening with MRIs can reduce risk of breast cancer mortality for survivors of childhood HL

Early screening with MRIs can reduce risk of breast cancer mortality for survivors of childhood HL

Researchers at Princess Margaret Cancer Centre have confirmed in a screening effectiveness study that early screening with MRIs can reduce breast cancer mortality for female survivors of childhood Hodgkin's lymphoma (HL) who received chest radiation. [More]
Higher body weight, taller stature during adolescence increase NHL risk

Higher body weight, taller stature during adolescence increase NHL risk

A new analysis indicates that higher body weight and taller stature during adolescence increase the risk of developing Non-Hodgkin's Lymphoma (NHL), a type of cancer of the lymphatic system. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society. [More]
HUYA, Eisai sign exclusive license agreement for HBI-8000 in Japan and other Asian countries

HUYA, Eisai sign exclusive license agreement for HBI-8000 in Japan and other Asian countries

HUYA Bioscience International President, CEO, Executive Chairman & Founder Dr. Mireille Gillings announced that Eisai Co., Ltd. has acquired from HUYA an exclusive license agreement for HBI-8000 in Japan, South Korea, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Singapore. [More]
Young African Americans, Hispanics fare worse when faced with Hodgkin lymphoma

Young African Americans, Hispanics fare worse when faced with Hodgkin lymphoma

African American and Hispanic adolescents and young adults fare far worse than their white counterparts when faced with a mostly curable type of cancer, Hodgkin lymphoma, a study by a UC Davis epidemiologist has found. [More]
African-American pediatric lymphoma patients have inferior outcomes compared to white and Hispanic peers

African-American pediatric lymphoma patients have inferior outcomes compared to white and Hispanic peers

Researchers from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine today published a study showing that African-American pediatric Hodgkin lymphoma patients have inferior overall survival to their white and Hispanic peers. [More]
New study finds significant racial disparity in patients with HIV and Hodgkin lymphoma

New study finds significant racial disparity in patients with HIV and Hodgkin lymphoma

A new study finds a significant racial disparity within a doubly troubled population of patients: those with HIV and Hodgkin lymphoma. In such cases, blacks are at significantly higher risk than whites of not receiving treatment for the cancer that in many cases would be effective. [More]
Rich Pharmaceuticals obtains FDA approval to begin Phase 1/2 study in AML and MDS patients

Rich Pharmaceuticals obtains FDA approval to begin Phase 1/2 study in AML and MDS patients

Rich Pharmaceuticals, Inc. is pleased to announce that the Company has received approval from the U.S. Food and Drug Administration to commence its Phase 1/2 clinical for the treatment of Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) patients. [More]
HBI-8000 granted orphan drug designation in Japan for treatment of peripheral T-cell lymphoma

HBI-8000 granted orphan drug designation in Japan for treatment of peripheral T-cell lymphoma

HUYA Bioscience International, Founder, CEO & Executive Chair, Dr. Mireille Gillings today announced that the Ministry of Health, Labour and Welfare granted HBI-8000 orphan drug designation in Japan for peripheral T-cell lymphoma (PTCL). [More]
New study examines single 'transformer' proteins involved in cancer

New study examines single 'transformer' proteins involved in cancer

A new study led by scientists at The Scripps Research Institute and St. Jude Children's Research Hospital shows how a protein involved in cancer twists and morphs into different structures. [More]
Innovative Phase II trial evaluates effectiveness of diabetes medication for lymphoma

Innovative Phase II trial evaluates effectiveness of diabetes medication for lymphoma

Cancer, it could be said, grows like a weed: rapidly, invasively, and with devastating impact on the place it infests. Also like a weed, cancer can't grow on its own — it needs nourishment, which it drains from the human body, just as weeds take nutrients in the soil away from other plants. [More]
New approaches to treating leukemia, lymphoma and myeloma

New approaches to treating leukemia, lymphoma and myeloma

New, highly targeted treatment approaches for leukemia, lymphoma, and myeloma to be presented today at the 57th American Society of Hematology Annual Meeting and Exposition represent a tremendous expansion of oral and intravenous therapy options for patients with blood cancers. [More]
Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

New research adds to a growing body of evidence that gene therapy, an experimental technique that involves correcting or replacing a person's mutated or malfunctioning genes, may improve health outcomes for patients with inherited bleeding and immune disorders as well as some forms of blood cancer. [More]
Many European hospitals fail to routinely test people at risk of HIV infection

Many European hospitals fail to routinely test people at risk of HIV infection

A new study reveals that many European hospitals fail to routinely test people who may be at risk of an HIV-infection. If tests were more widely offered in the healthcare system, fewer HIV-patients would go unnoticed, especially in Northern Europe. [More]
Patients with kidney failure at increased risk of developing different types of cancer

Patients with kidney failure at increased risk of developing different types of cancer

For patients with kidney failure, poor kidney function and immunosuppressant medications may increase their risk of developing different types of cancer. The findings, which are published in a study appearing in an upcoming issue of the Journal of the American Society of Nephrology, suggest the need for persistent cancer screening and prevention in these patients. [More]
Drug combination produces long-term responses in patients with mantle cell lymphoma

Drug combination produces long-term responses in patients with mantle cell lymphoma

New research from Moffitt Cancer Center and its collaborators find that the drug combination rituximab plus lenalidomide was effective and produced long-term responses in patients with mantle cell lymphoma. [More]
Phase I clinical trial shows investigational anticancer therapeutic is safe, tolerable in lymphoma patients

Phase I clinical trial shows investigational anticancer therapeutic is safe, tolerable in lymphoma patients

Results from a phase I clinical trial showed that the first-in-class, investigational, anticancer therapeutic pevonedistat was safe, tolerable, and had some anticancer activity in heavily pretreated patients with relapsed/refractory lymphoma. [More]
Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented

Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented

Takeda Pharmaceutical Company Limited today announced that it will present Phase 3 data from the TOURMALINE-MM1 ixazomib clinical trial at the 57th American Society of Hematology (ASH) Annual Meeting to be held in Orlando, Florida from December 5 to 8, 2015. [More]
Innovative immunotherapy clinical trial underway at The University of Kansas Cancer Center

Innovative immunotherapy clinical trial underway at The University of Kansas Cancer Center

A novel immunotherapy clinical trial underway now at The University of Kansas Cancer Center has enrolled the first patients in the world to receive what many doctors and researchers believe is the future of cancer treatment. [More]
Advertisement